Influenza Vaccine and COVID-19 Pandemic: Could This Vaccine Help Limit the Potential Adverse Consequences of SARS-CoV-2?
| Author | Reza Mosaed | en |
| Author | Hossein Fasihi | en |
| Author | Amir Norouzi | en |
| Author | Vahid Anjomanian | en |
| Author | Mohammad Afshar Ardalan | en |
| Author | Farshid Alazmani Noodeh | en |
| Author | Ali Reza Khoshdel | en |
| Orcid | Hossein Fasihi [0000-0001-8184-793X] | en |
| Issued Date | 2022-12-31 | en |
| Abstract | The COVID-19 pandemic has prompted researchers to find treatments and vaccines to control SARS-CoV-2. There are some hypotheses about the benefit of respiratory virus vaccines, like MMR, for COVID-19 pneumonia severity, morbidity, and mortality. The influenza vaccine is one of the most frequently used respiratory virus vaccines covered by one of the Iranian insurance institutes. We have a symmetrical group of participants that have received this vaccine that could be compared with each other. We compared 3,379 persons aged 20 - 75 years for the effect of the influenza vaccine on COVID-19 mortality. We ultimately found that it does not affect mortality caused by COVID-19 pneumonia, but it can decrease the hospitalization cost in people over 65 years with a history of chronic disease. | en |
| DOI | https://doi.org/10.5812/ijpr-127032 | en |
| Keyword | COVID-19 | en |
| Keyword | Influenza | en |
| Keyword | Vaccine | en |
| Keyword | Pneumonia | en |
| Keyword | Mortality | en |
| Publisher | Brieflands | en |
| Title | Influenza Vaccine and COVID-19 Pandemic: Could This Vaccine Help Limit the Potential Adverse Consequences of SARS-CoV-2? | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijpr-21-1-127032.pdf
- Size:
- 107.71 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF